Dr. Reddy's Laboratories/$RDY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ticker
$RDY
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Hyderabad, India
Employees
27,811
ISIN
US2561352038
Website
RDY Metrics
BasicAdvanced
$13B
19.42
$0.78
0.39
$0.08
0.53%
Price and volume
Market cap
$13B
Beta
0.39
52-week high
$16.89
52-week low
$12.26
Average daily volume
1.7M
Dividend rate
$0.08
Financial strength
Current ratio
1.918
Quick ratio
1.138
Long term debt to equity
2.332
Total debt to equity
13.87
Dividend payout ratio (TTM)
11.78%
Interest coverage (TTM)
26.35%
Profitability
EBITDA (TTM)
1,025.214
Gross margin (TTM)
58.50%
Net profit margin (TTM)
17.37%
Operating margin (TTM)
22.90%
Effective tax rate (TTM)
25.45%
Revenue per employee (TTM)
$135,130
Management effectiveness
Return on assets (TTM)
10.58%
Return on equity (TTM)
18.53%
Valuation
Price to earnings (TTM)
19.42
Price to revenue (TTM)
3.368
Price to book
3.31
Price to tangible book (TTM)
4.91
Price to free cash flow (TTM)
85.917
Free cash flow yield (TTM)
1.16%
Free cash flow per share (TTM)
17.68%
Dividend yield (TTM)
0.53%
Forward dividend yield
0.53%
Growth
Revenue change (TTM)
16.61%
Earnings per share change (TTM)
1.46%
3-year revenue growth (CAGR)
14.94%
10-year revenue growth (CAGR)
8.25%
3-year earnings per share growth (CAGR)
33.73%
10-year earnings per share growth (CAGR)
10.08%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about RDY
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
Bulls say / Bears say
Dr. Reddy's Laboratories has entered into a definitive agreement to acquire consumer healthcare brands in the Nicotine Replacement Therapy category from Haleon plc, including the global brand Nicotinell, enhancing its consumer healthcare portfolio and global market presence. (sharekhan.com)
The company reported a 16.61% increase in revenue in 2024 compared to the previous year, indicating strong financial performance and growth potential. (stockanalysis.com)
Analyst recommendations for Dr. Reddy's Laboratories include 6 'Strong Buy' and 8 'Buy' ratings, reflecting positive sentiment and confidence in the company's future prospects. (economictimes.indiatimes.com)
Dr. Reddy's Laboratories' manufacturing unit in Andhra Pradesh received four observations from the US FDA, which could indicate potential regulatory challenges. (sharekhan.com)
The company has shown a poor revenue growth of 13.43% over the past three years, which may raise concerns about its long-term growth trajectory. (finology.in)
Dr. Reddy's Laboratories' stock has declined to a new 52-week low, currently priced at Rs 1,111.5, dipping below the previous low of Rs 1,120.0, indicating potential investor concerns. (economictimes.indiatimes.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RDY Financial Performance
Revenues and expenses
RDY Earnings Performance
Company profitability
RDY News
AllArticlesVideos
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Business Wire·2 weeks ago
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's
CNBC International TV·1 month ago
Dr. Reddy's Q4 & Full Year FY25 Financial Results
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dr. Reddy's Laboratories stock?
Dr. Reddy's Laboratories (RDY) has a market cap of $13B as of June 20, 2025.
What is the P/E ratio for Dr. Reddy's Laboratories stock?
The price to earnings (P/E) ratio for Dr. Reddy's Laboratories (RDY) stock is 19.42 as of June 20, 2025.
Does Dr. Reddy's Laboratories stock pay dividends?
Yes, the Dr. Reddy's Laboratories (RDY) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.08083 and the yield is 0.53%. Dr. Reddy's Laboratories has a payout ratio of 11.78% on a trailing twelve-month basis.
When is the next Dr. Reddy's Laboratories dividend payment date?
The next Dr. Reddy's Laboratories (RDY) dividend payment date is unconfirmed.
What is the beta indicator for Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.